LLY

1,075.18

+0.27%↑

JNJ

207.23

+0.6%↑

ABBV

227.72

+0.26%↑

UNH

325.11

-0.71%↓

AZN

91.53

+0.2%↑

LLY

1,075.18

+0.27%↑

JNJ

207.23

+0.6%↑

ABBV

227.72

+0.26%↑

UNH

325.11

-0.71%↓

AZN

91.53

+0.2%↑

LLY

1,075.18

+0.27%↑

JNJ

207.23

+0.6%↑

ABBV

227.72

+0.26%↑

UNH

325.11

-0.71%↓

AZN

91.53

+0.2%↑

LLY

1,075.18

+0.27%↑

JNJ

207.23

+0.6%↑

ABBV

227.72

+0.26%↑

UNH

325.11

-0.71%↓

AZN

91.53

+0.2%↑

LLY

1,075.18

+0.27%↑

JNJ

207.23

+0.6%↑

ABBV

227.72

+0.26%↑

UNH

325.11

-0.71%↓

AZN

91.53

+0.2%↑

Search

Charles River Laboratories International Inc

Chiusa

SettoreSettore sanitario

202.83 2.96

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

193.74

Massimo

204.12

Metriche Chiave

By Trading Economics

Entrata

2.9M

56M

Vendite

-27M

1B

P/E

Media del settore

592.3

76.798

EPS

2.43

Margine di Profitto

5.529

Dipendenti

18,700

EBITDA

-23M

198M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+1.77% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

950M

9.8B

Apertura precedente

199.87

Chiusura precedente

202.83

Notizie sul Sentiment di mercato

By Acuity

15%

85%

17 / 374 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

Charles River Laboratories International Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

22 dic 2025, 23:54 UTC

I principali Market Mover

Novo Nordisk ADRs Gain on FDA Approval of First GLP-1 in Pill Form

22 dic 2025, 19:08 UTC

Acquisizioni, Fusioni, Takeovers

Correction to Alphabet to Buy Intersect Article

22 dic 2025, 17:21 UTC

Acquisizioni, Fusioni, Takeovers

Alphabet to Buy Intersect for $4.75 Billion as AI-Investment Plans Grow -- Update

22 dic 2025, 16:46 UTC

Acquisizioni, Fusioni, Takeovers

Alphabet to Buy Intersect for $4.75 Billion in Cash

22 dic 2025, 23:50 UTC

Discorsi di Mercato

Nikkei May Decline as Yen Rebounds -- Market Talk

22 dic 2025, 23:42 UTC

Discorsi di Mercato

Gold Hits Record High Amid Rising Geopolitical Risks -- Market Talk

22 dic 2025, 22:31 UTC

Utili

Zhejiang Sanhua Intelligent Controls: Higher Demand for Air-Conditioning Components Supported Results >002050.SZ

22 dic 2025, 22:31 UTC

Utili

Zhejiang Sanhua Intelligent Controls: Higher Demand for Refrigeration Supported Results >002050.SZ

22 dic 2025, 22:30 UTC

Utili

Zhejiang Sanhua Intelligent Controls Sees 2025 Net CNY3.87B, Up 25% on Year >002050.SZ

22 dic 2025, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

22 dic 2025, 21:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

22 dic 2025, 21:37 UTC

Acquisizioni, Fusioni, Takeovers

Capricorn: Project Is Contiguous to Capricorn's Golden Range, Fields Find Tenure

22 dic 2025, 21:36 UTC

Acquisizioni, Fusioni, Takeovers

Capricorn to Pay A$500,000 Cash, A$4M in New Shares

22 dic 2025, 21:35 UTC

Acquisizioni, Fusioni, Takeovers

Capricorn to Acquire Prospective Package From Tempest Minerals

22 dic 2025, 21:35 UTC

Acquisizioni, Fusioni, Takeovers

Capricorn Metals to Buy Yalgoo Project Tenement Package for A$4.5M

22 dic 2025, 20:54 UTC

Acquisizioni, Fusioni, Takeovers

Middle West Partners Buys Paul Stuart From Mitsui & Co.

22 dic 2025, 20:52 UTC

Acquisizioni, Fusioni, Takeovers

HCL Technologies: HCLSoftware to Acquire Jaspersoft From Cloud Software Group >532281.BY

22 dic 2025, 20:09 UTC

Discorsi di Mercato

U.S. Natural Gas Settles Lower in Choppy Trade -- Market Talk

22 dic 2025, 19:56 UTC

Discorsi di Mercato

Crude Gains as U.S. Increases Actions Against Venezuela -- Market Talk

22 dic 2025, 19:49 UTC

Acquisizioni, Fusioni, Takeovers

A Topsy-Turvy Year for Oracle and the Ellisons Will Bleed into 2026 -- Barrons.com

22 dic 2025, 19:23 UTC

Discorsi di Mercato

Mexico's Inflation Seen Easing in Early December -- Market Talk

22 dic 2025, 19:23 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

22 dic 2025, 19:02 UTC

Discorsi di Mercato

Global Energy Roundup: Market Talk

22 dic 2025, 19:02 UTC

Discorsi di Mercato

Precious Metals Climb to New Heights -- Market Talk

22 dic 2025, 18:45 UTC

Discorsi di Mercato

Canadian Trade-Exposed Industries At Forefront of Job Weakness -- Market Talk

22 dic 2025, 18:30 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Intersect Selling Portion of Assets as Part of Alphabet Deal -- Market Talk

22 dic 2025, 18:23 UTC

Acquisizioni, Fusioni, Takeovers

What Yogi Berra Would Say About the Talks to Take Over Warner Bros. Discovery -- Barrons.com

22 dic 2025, 17:20 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

22 dic 2025, 17:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

22 dic 2025, 17:06 UTC

Acquisizioni, Fusioni, Takeovers

Alphabet to Buy Intersect for $4.75B as AI-Investment Plans Grow -- Update

Confronto tra pari

Modifica del prezzo

Charles River Laboratories International Inc Previsione

Obiettivo di Prezzo

By TipRanks

1.77% in crescita

Previsioni per 12 mesi

Media 200.55 USD  1.77%

Alto 225 USD

Basso 170 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Charles River Laboratories International Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

11 ratings

7

Acquista

4

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

117.16 / 144.77Supporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

17 / 374 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat